Aims: To investigate the therapeutic potential of itraconazole in oral squamous cell carcinoma (OSCC) and its molecular mechanism.
Materials And Methods: The in vitro anti-cancer effects of itraconazole was determined by CCK-8 assay and colony formation assay. Transwell and wound healing assays were used to examine cell invasion and migration. The in vivo therapeutic efficacy of itraconazole was assessed by OSCC patient-derived xenograft (PDX) model. Western blot was performed to explore the anti-cancer mechanism.
Key Findings: Itraconazole inhibited cell proliferation and colony formation of OSCC cells in a time and concentration dependent manner; induced cell cycle arrest and apoptosis, as well as inhibited cell invasion and migration. In the OSCC PDX model, itraconazole impeded tumor growth, reduced Ki-67 expression and induced apoptosis. Itraconazole downregulated the protein expression of Hedgehog pathway to inhibit proliferation and migration of oral squamous cell carcinoma cells, which can be revised by recombinant human sonic hedgehog protein (rSHH).
Significance: Itraconazole showed anti-cancer effects on OSCC via inhibiting the Hedgehog pathway.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.lfs.2020.117695 | DOI Listing |
Pak J Pharm Sci
January 2025
The Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
In order to make the drugs can cure the tumor precisely, this paper establishes the tumor immune dynamic model through the differential equation of tumor growth and analyzes the persistence of the tumor immune model. Research on dual anticancer drugs and commonly used coupling methods is carried out to complete the synthesis of polyethylene glycol dual anticancer drug couplers and the antitumor activity is analyzed to derive the degree of inhibition of polyethylene glycol dual anticancer drugs on tumor activity. From the four judging criteria, it was concluded that the polyethylene glycol bis-anti-cancer drug has a better curative effect on tumor cells.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Nuclear Research Centre of Birine, Ain Oussera, Djelfa 17200, Algeria. Electronic address:
There is a need for advanced developments to battle aggressive breast cancer variations and to address treatment resistance. In cancer therapy, ZnO nanoparticles (NPs) possess the ability to selectively and effectively induce apoptosis in cancer cells. There is an urgent necessity to create novel anti-cancer therapies, and recent studies indicate that ZnO nanoparticles have significant promise.
View Article and Find Full Text PDFInt J Biol Macromol
January 2025
Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China. Electronic address:
Colon cancer is a leading cause of cancer-related morbidity and mortality worldwide, necessitating advancements in therapeutic strategies to improve outcomes. Current treatment modalities, including surgery, chemotherapy, and radiation, are limited by systemic toxicity, low drug utilization rates, and off-target effects. Colon-targeted drug delivery systems (CDDS) offer a promising alternative by leveraging the colon's unique physiology, such as near-neutral pH and extended transit time, to achieve localized and controlled drug release.
View Article and Find Full Text PDFPhytomedicine
January 2025
School of Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China. Electronic address:
Background: Melittin, a major peptide component of bee venom, has demonstrated promising anti-cancer activity across various preclinical cell models, making it a potential candidate for cancer therapy. However, its molecular mechanisms, particularly in ovarian cancer, remain largely unexplored. Ovarian cancer is a life-threatening gynecological malignancy with poor clinical outcomes and limited treatment options.
View Article and Find Full Text PDFExpert Opin Biol Ther
January 2025
OU Stephenson Cancer Center, Oklahoma City.
Introduction: Antibody-drug conjugates (ADCs) are a rapidly evolving class of anti-cancer drugs with a significant impact on management of hematological malignancies including diffuse large B-cell lymphoma (DLBCL). ADCs combine a cytotoxic drug (a.k.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!